Concomitant administration of paclitaxel with CYP3A4 inhibitor causes an increase in taxane concentrations with an increased risk of severe myelosuppression and peripheral neuropathy (Leandro-García et al., 2012). The gene discussed is CYP3A4; the disease is peripheral neuropathy.